Taurine for Cardiovascular Disease

Verdict: Lowers blood pressure modestly; heart outcomes unproven

Taurine produces a small but consistent drop in blood pressure in trials, but there is no evidence it actually prevents heart attacks, heart failure, or cardiovascular death. It is best viewed as a minor add-on, not a treatment for cardiovascular disease.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The preliminary (B) grade rests entirely on surrogate markers rather than real cardiovascular outcomes. Three meta-analyses are consistent: a 2018 pooled analysis found roughly 3 mmHg reductions in systolic and diastolic pressure (PMID 30006901), a 2024 review of 20 RCTs reported a 4.0 mmHg systolic and 1.4 mmHg diastolic fall plus a small rise in ejection fraction (PMID 39148075), and a 2025 review of 34 RCTs found a 4.38 mmHg systolic and 2.54 mmHg diastolic drop (PMID 41275513). These effects are statistically significant but clinically modest.

The grade stops at B because the hard evidence is missing. No randomized trial has tested whether taurine reduces heart attacks, strokes, or death. The heart-failure trials are tiny and short (PMID 21334852, n=29, two weeks), and the widely cited 2023 anti-aging finding (PMID 37289866) is an observational cohort that shows association, not cause. Population-mixing across the meta-analyses further limits how far any single result applies.

Regulators and clinics endorse only its safety, not heart benefits. The US FDA has 'no questions' about taurine as a food ingredient but approves no cardiovascular claim, and the WHO/JECFA notes 'no safety concern at current levels of intake when used as a flavouring agent.' The Mayo Clinic cautions that taurine combined with caffeine in energy drinks can stress the heart's electrical system, a real risk for people with existing heart conditions.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.59
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
75%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.588
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

The Effects of Oral Taurine on Resting Blood Pressure in Humans: a Meta-Analysis
PMID: 30006901 2018 統合分析 n = 103
Finding: Modest but significant SBP reduction (Hedges' g = -0.70, p < 0.0001) and DBP reduction (Hedges' g = -0.62, p < 0.0001); ~3 mmHg absolute reduction in both.
Effect size: Hedges' g -0.70 SBP; -0.62 DBP
View on PubMed
Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis
PMID: 39148075 2024 系統性回顧 n = 808
Finding: Taurine significantly reduced HR (-3.579 bpm, p=0.004), SBP (-3.999 mmHg, p=0.017), DBP (-1.435 mmHg, p=0.007), NYHA class (-0.403, p<0.001), and increased LVEF (+4.981%, p=0.004); includes heart failure subgroup.
🟢 High quality Government Effect size: WMD: SBP -4.0 mmHg; DBP -1.4 mmHg; LVEF +5.0%
View on PubMed
Effects of Oral Taurine Supplementation on Cardiometabolic Risk Factors: A Meta-analysis and Systematic Review of RCTs
PMID: 41275513 2025 系統性回顧
Finding: SBP reduced by 4.38 mmHg (95% CI -7.26 to -1.50); DBP reduced by 2.54 mmHg (95% CI -3.97 to -1.11); also significant reductions in fasting glucose, HbA1c, triglycerides.
🟢 High quality Government Effect size: MD SBP -4.38 mmHg; DBP -2.54 mmHg
View on PubMed
Taurine deficiency as a driver of aging
PMID: 37289866 2023 Cohort n = 11,966
Finding: Lower circulating taurine inversely associated with multiple cardiometabolic risk factors (T2D, BMI, blood pressure correlates); taurine declines with aging across species; human RCTs called for.
Government
View on PubMed
Effect of taurine supplementation on exercise capacity of patients with heart failure
PMID: 21334852 2011 RCT (open-label) n = 29
Finding: Taurine group showed significant improvement in all exercise capacity measures (p<0.0001); placebo showed no change. Mean LVEF ~29%.
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
FDA has no questions source↗
L4b EU EFSA
Cautious
L4d TW TFDA / 衛福部
Neutral
本品可於各類食品中視實際需要適量使用,限於補充食品中不足該營養素時使用。 source↗
L4e WHO
Not addressed
JECFA (Meeting 69, 2008): 'No safety concern at current levels of intake when used as a flavouring agent.' Codex Alimentarius (CXS 72-1981): taurine is an optional (not mandatory) ingredient in infant formula; mandatory addition is not considered necessary. source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Energy drinks contain ingredients such as caffeine, taurine and guarana that affect the heart, the heart's electrical system and the heart's muscular pump. source↗
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cardiovascular-disease-INT-taurine-001 繁體中文版 →